Walvax Biotechnology Co., Ltd. (SHE:300142)

Walvax Biotechnology Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	3,505	3,764	4,365	3,873	3,443	1,962
Cash & Short-Term Investments	3,505	3,764	4,365	3,873	3,443	1,962
Cash Growth	-14.77%	-13.77%	12.68%	12.49%	75.54%	-17.62%
Accounts Receivable	2,379	2,410	3,101	3,577	2,481	2,004
Other Receivables	86.21	58.8	114.18	416.13	774.86	304.77
Receivables	2,465	2,468	3,215	3,993	3,255	2,308
Inventory	711.02	752.59	1,035	995.81	873.59	483.56
Other Current Assets	68.18	82.22	119.21	86.25	107.94	26.77
Total Current Assets	6,749	7,067	8,733	8,948	7,680	4,780
Property, Plant & Equipment	4,047	4,079	3,768	3,161	2,604	1,590
Long-Term Investments	941.13	1,638	1,057	1,292	1,491	1,605
Goodwill	33.66	33.66	33.66	33.66	33.66	33.66
Other Intangible Assets	1,001	1,035	1,086	1,167	434.98	271.68
Long-Term Accounts Receivable	3.46	7.27	-	-	-	-
Long-Term Deferred Tax Assets	100.81	104.56	103.44	124.84	168.01	138.55
Long-Term Deferred Charges	521.05	513.86	473.48	309.38	1,022	890
Other Long-Term Assets	967.13	246.62	333.54	300.2	240.63	329.41
Total Assets	14,364	14,724	15,589	15,336	13,674	9,638
Accounts Payable	1,661	1,568	1,805	1,836	1,258	607.79
Accrued Expenses	28.94	549.81	722.05	1,189	754.71	497.41
Short-Term Debt	-	-	320.27	97.18	310	40
Current Portion of Long-Term Debt	25.18	38.98	8.79	-	-	-
Current Portion of Leases	-	7.85	21.88	23.35	4.6	-
Current Income Taxes Payable	7.65	-	14.13	19.47	2.03	68.54
Current Unearned Revenue	34.02	106.18	160.47	66.78	35.29	9.68
Other Current Liabilities	304.45	99.4	151.25	276.22	870.61	198.55
Total Current Liabilities	2,061	2,370	3,204	3,509	3,235	1,422
Long-Term Debt	433.34	433.34	434.9	314.24	-	-
Long-Term Leases	10.8	11.77	20.6	27.74	1.06	-
Long-Term Unearned Revenue	268.03	278.44	423.33	404.53	344.3	256.18
Long-Term Deferred Tax Liabilities	55.19	55.91	68.71	90.94	94.56	112.27
Other Long-Term Liabilities	47.31	67	42.08	-	-	-
Total Liabilities	2,876	3,216	4,194	4,346	3,675	1,790
Common Stock	1,599	1,599	1,607	1,607	1,601	1,546
Additional Paid-In Capital	4,549	4,549	4,900	4,965	4,772	3,262
Retained Earnings	3,113	3,110	2,984	2,580	1,895	1,546
Treasury Stock	-	-	-358.63	-286.42	-	-
Comprehensive Income & Other	171.28	171.28	217.18	217.18	216.33	190.88
Total Common Equity	9,432	9,430	9,349	9,084	8,484	6,545
Minority Interest	2,056	2,078	2,046	1,906	1,515	1,303
Shareholders' Equity	11,488	11,508	11,395	10,990	9,999	7,848
Total Liabilities & Equity	14,364	14,724	15,589	15,336	13,674	9,638
Total Debt	469.32	491.94	806.42	462.51	315.67	40
Net Cash (Debt)	3,036	3,272	3,558	3,411	3,128	1,922
Net Cash Growth	-8.23%	-8.05%	4.31%	9.06%	62.77%	-19.30%
Net Cash Per Share	1.91	2.05	2.22	2.13	1.99	1.23
Filing Date Shares Outstanding	1,599	1,599	1,599	1,601	1,601	1,546
Total Common Shares Outstanding	1,599	1,599	1,599	1,601	1,601	1,546
Working Capital	4,688	4,697	5,529	5,440	4,445	3,358
Book Value Per Share	5.90	5.90	5.85	5.67	5.30	4.23
Tangible Book Value	8,398	8,361	8,230	7,883	8,016	6,239
Tangible Book Value Per Share	5.25	5.23	5.15	4.92	5.01	4.04
Buildings	-	953.95	948.5	767.91	541.68	487.84
Machinery	-	2,196	2,093	1,580	1,235	930.76
Construction In Progress	-	2,114	1,645	1,509	1,527	762.51

Source: S&P Global Market Intelligence. Standard template. Financial Sources.